bioAffinity Technologies, Inc. BIAF

BIAF Company Overview

bioAffinity Technologies, Inc. is a U.S.-based biotechnology and diagnostics company focused on the development of noninvasive diagnostic tests and targeted therapeutics, primarily for lung disease and cancer detection. The company operates in the healthcare and life sciences sectors, with activities spanning diagnostics, laboratory services, and cancer therapeutics research. Its primary commercial focus has been the development and commercialization of CyPath® Lung, a flow cytometry-based diagnostic test designed to aid in the detection of lung cancer in high-risk patients. The company also conducts laboratory operations through Precision Pathology Laboratory Services, which provides pathology and clinical laboratory testing services.

The company’s revenue drivers include diagnostic testing services, laboratory operations, and the potential future commercialization of proprietary diagnostic technologies and therapeutics. bioAffinity Technologies positions itself around noninvasive diagnostics that aim to improve early detection rates while reducing unnecessary invasive procedures. The company was founded in 2014 and later became publicly traded on Nasdaq under the ticker BIAF. Its evolution has included expansion from research-stage biomarker development into commercial laboratory operations and clinical deployment initiatives tied to pulmonary disease diagnostics.